Oryl Photonics and WP3
Bringing cutting-edge research to the pharmaceutical industry requires more than innovation—it demands a clear path to commercialization. In WP3, we focus on business development, ensuring that the FASS instrument not only meets scientific needs but is also market-ready.
Our efforts include:
- Developing and validating a business plan for commercialization and go-to-market strategies.
- Protecting intellectual property rights to safeguard innovations.
- Meeting regulatory standards and establishing a robust supply chain for production.
Leading this effort is Oryl Photonics, an innovative technology company and EPFL spin-off dedicated to redefining solubility and aggregation measurements in the pharmaceutical industry. Using advanced nonlinear light scattering, Oryl is driving the development of the FASS instrument with contributions to:
- Prototype development in WP1
- Business development in WP3: Introducing the FASS instrumen to the market and establishing its value proposition for pharmaceutical and biotechnological companies.
By combining Oryl’s expertise with the WP3 team’s focus on strategy, we’re transforming the FASS instrument into a viable product that saves resources and advances drug research and development.